作者
Jon M. Steichen,Ying‐Cing Lin,Colin Havenar‐Daughton,Simone Pecetta,Gabriel Ozorowski,Jordan R. Willis,Laura Toy,Devin Sok,Alessia Liguori,Sven Kratochvil,Jonathan L. Torres,Oleksandr Kalyuzhniy,Eleonora Melzi,Daniel W. Kulp,Sebastian Raemisch,Xiaozhen Hu,Steffen M. Bernard,Erik Georgeson,Nicole Phelps,Yumiko Adachi,Michael Kubitz,Elise Landais,Jeffrey C. Umotoy,Amanda M. Robinson,Bryan Briney,Ian A. Wilson,Dennis R. Burton,Andrew B. Ward,Shane Crotty,Facundo D. Batista,William R. Schief
摘要
Engineering better bnAbs A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197